Tadalafil Powder CAS 171596-29-5 Powder Raw Material

CAS: 171596-29-5

MF: C22H19N3O4

Specification​: 99% min Tadalafil

Sample:  Tadalafil Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Tadalafil Powder Usage and Synthesis:

Henrikang provides quality Tadalafil Powder Raw Material BP EP USP CAS 171596-29-5 . We are one of the leading and professional China Pharmaceutical Raw Material manufacturers and suppliers in this field. High quality, Best stability and competitive price are favorable our main age to contact us for more information. Tadalafil (Tadalafil) has a molecular formula of C22H19N3O4 and a molecular weight of 389.4. It has been widely used in the treatment of male erectile dysfunction since 2003, and its trade name is Cialis. It takes effect 30 minutes after administration, but its best curative effect is 2 hours after the onset of effect, and the curative effect can last for 36 hours, and its curative effect is not affected by food. Tadalafil is used to treat erectile dysfunction (ED) and pulmonary hypertension in men.

Pharmacokinetics of Tadalafil Powder:

Tadanafil and sildenafil belong to the same selective type 5 phosphodiesterase (PDE5), but its structure is different from that of the latter, and high fat diet does not interfere with its absorption. Under sexual stimulation, nitric oxide synthase (NOS) in penile nerve endings and vascular endothelial cells catalyzes the synthesis of nitric oxide (NO) from the substrate L-arginine. NO activates guanylate cyclase, which converts guanyl triphosphate into cyclic guanosine phosphate (cGMP), which activates cyclic guanosine phospho-dependent protein kinase, resulting in a decrease in calcium concentration in smooth muscle cells, resulting in relaxation of the smooth muscle of the corpus cavernosum and erection.

Clinical Application of Tadalafil Powder:

Tadalafil Powder is a phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction in men. A second generation phosphodiesterase 5 inhibitor is used for the treatment of bo dysfunction in men. Tadanafil affects this by inhibiting PDES. GMP degradation, so when used in combination with nitric acetogens may cause an extreme drop in blood pressure and increase the risk of syncope. CY3PA4 inducer can reduce the abiotic availability of tadanab. Combining with rifampicin, cimetidine, erythromycin, clarithromycin, itraconwa, ketoconwa and HVI protease inhibitors may increase the blood concentration of this product. Attention should be paid to the dose.